Key Highlights

  • Telix Pharmaceuticals (ASX: TLX) has grown from a speculative radiopharmaceutical hopeful into one of the ASX's larger and better-followed healthcare names, and a
  • Telix's commercial base is already substantial.
  • The BiPASS study evaluates PSMA-PET imaging — using Illuccix and Gozellix — in the pre-biopsy setting, an earlier point in the patient pathway
  • This matters because expanding PSMA-PET into earlier, larger patient populations — and securing a reimbursement pathway tied to a distinct approval — is

Telix Pharmaceuticals (ASX: TLX) has grown from a speculative radiopharmaceutical hopeful into one of the ASX's larger and better-followed healthcare names, and a September 2026 clinical milestone has put its pipeline back at the centre of the story. On 2 September 2026, the company announced it had completed patient enrollment in its Phase 3 BiPASS study — a development that, combined with progress on the regulatory front, sharpens the question of what comes next for its prostate-cancer imaging franchise.

Telix's commercial base is already substantial. The company is best known for Illuccix, its approved PSMA-PET imaging agent for prostate cancer, and it has continued to broaden its portfolio, including the newer imaging agent Gozellix. That existing Revenue engine is important context: unlike many biotechs chasing a first approval, Telix is funding clinical expansion from a growing commercial business.

What BiPASS is testing

The BiPASS study evaluates PSMA-PET imaging — using Illuccix and Gozellix — in the pre-biopsy setting, an earlier point in the patient pathway than current practice. Telix has said it reached alignment with the US Food and Drug Administration on a New Drug Application pathway that, if the product is ultimately approved, would support reimbursement as a new product and broaden patient access. Completing enrollment is a necessary step toward read-out and any subsequent regulatory filing.

This matters because expanding PSMA-PET into earlier, larger patient populations — and securing a reimbursement pathway tied to a distinct approval — is exactly the kind of addressable-market expansion that can extend a commercial franchise. It is, however, a step in a process: enrollment completion is not the same as positive trial results or approval.

A Business with momentum

Telix has paired clinical progress with commercial scale. The company reported second-quarter 2026 revenue of about US$247 million, pointing to continued momentum in its core imaging business, and released its first-half 2026 results on 20 August 2026. Reported Earnings Per Share of roughly 13.7 cents indicate the group has moved beyond the cash-burning phase typical of the sector. Governance has also evolved, with David Gill appointed Chair from 1 September 2026.

The share price reflects the market's re-rating of the company over several years, closing near $24.42 at 30 June 2025, up sharply from earlier levels — a reminder that a good deal of optimism is already embedded in the stock.

Catalysts and risks to watch

The clear catalysts ahead are the BiPASS trial read-out and any subsequent FDA submission and decision, continued growth in Illuccix and Gozellix sales, and progress across Telix's broader therapeutic and diagnostic pipeline. Guidance updates and quarterly revenue prints will show whether commercial momentum is holding.

The risks are equally concrete. Clinical Trials can disappoint even after enrollment completes; regulatory timelines and outcomes are uncertain; competition in PSMA imaging and radioligand therapy is rising; and a premium valuation leaves limited room for error if results or approvals slip. Manufacturing, isotope Supply and reimbursement dynamics add further complexity in radiopharmaceuticals.

A balanced view

So, could this be a major catalyst? Completing BiPASS enrollment, alongside an agreed FDA pathway, is a genuine and verifiable step that keeps a potentially franchise-expanding opportunity on track — but it is a milestone on the road, not a destination. The greater near-term support for the Investment case is Telix's demonstrated commercial scale, with quarterly revenue in the hundreds of millions and positive reported earnings. For investors, the appeal is a profitable, growing radiopharmaceutical company with real pipeline optionality; the caution is a full valuation and the inherent uncertainty of clinical and regulatory outcomes. The trial read-out, when it comes, will be the more decisive test.